Skip to main content

As Arrowhead falters, lungs remain a tough target for RNA drugs

Submitted by admin on
snippet

Safety concerns in animal tests led Arrowhead Pharmaceuticals to suspend testing of a closely watched drug for cystic fibrosis, the latest setback for an RNA-based medicine against the genetic lung disease.

Source
BioPharma Dive

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Submitted by admin on
snippet

Johnson & Johnson has paid $175 million upfront for the global rights to Arrowhead’s phase 1/2 RNAi hepatitis B drug. The outlay, plus $1.6 billion in milestones, has bought J&J a drug that slashed levels of hepatitis B virus in a small, early-phase assessment.

Source
Fierce Biotech